



May 10, 2010

MedImmune, Inc.
One MedImmune Way
Gaithersburg, Maryland 20878

GlaxoSmithKline
709 Swedeland Road
P.O. Box 1539
King of Prussia, PA
19406-0939

Tel. 610 270 4800
Fax. 610 270 7777
www.gsk.com

Attn: Scott Alban


Re: MedImmune, Inc. - US Patent 7,351,533
Application for Extension of Patent Term under 35 U.S.C. §112

Dear Mr. Alban:

We are pleased with the approval by the Federal Food and Drug Administration (FDA) in the United States of Biologics License Application (BLA) #BL 125259/0 for CERVARIX® on October 16, 2009. BLA BL # BL125259/0 was submitted by Glaxo Group Ltd d/b/a/ GlaxoSmithKline, with an effective date of March 29, 2007 and references IND# BB-IND-7920 submitted by MedImmune on September 8, 1998, as per our License Agreements of December 10, 1997 and February 2, 2005.

The approved products are CERVARIX® containing recombinant L1 protein of oncogenic Human Papillomavirus (HPV) types 16 and 18 in the form of Virus Like Particles, which are covered by one or more claims of U.S. Patent No. 7,351,533 ("the '533 patent") assigned to MedImmune, Inc. It is our understanding that for this reason an Extension of Patent Term under 35 U.S.C. §156 may be obtained based on agency review to approve commercialization of CERVARIX®. For this purpose, GlaxoSmithKline hereby authorizes MedImmune, Inc. to rely upon the activities of GlaxoSmithKline before the FDA in submitting an application for an Extension of the Patent Term of its '533 patent.

Very truly yours,


Marcus J. W. Dalton
VP, Global Head, Bio Patents
GlaxoSmithKline